<DOC>
	<DOC>NCT01088360</DOC>
	<brief_summary>The purpose of this study is to compare the incidence rates of targeted infections, malignancies and mortality among patients with rheumatoid arthritis who are treated with abatacept and those who are treated with other anti-rheumatic medications.</brief_summary>
	<brief_title>Safety Study of Abatacept to Treat Rheumatoid Arthritis (B)</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>Signed informed consent Diagnosis of rheumatoid arthritis &gt; 18 years at index treatment initiation or switch Starting treatment with abatacept or new diseasemodifying antirheumatic drug (including switching or adding) or biologic disease modifying drug. Read/write English</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>